Project ALS has selected Medidata’s biomarker discovery solution for its research projects, aiming to improve understanding of the ALS disease process and develop new therapeutic strategies.
Domainex is set to support Lunac’s discovery project for anticoagulant therapies with reduced bleeding risk, following the developer’s novel target validation.
Aiming to facilitate and accelerate discovery of biologics, Aridis’ Apex platform can also discover antibodies against viruses ‘within one day of a pandemic’.
Leveraging Eurofins’ pharmacology, in-vitro models and ADME capabilities, PharmaResources aims to accelerate drug discovery for its clients in small molecule drug R&D.
BioIVT taps into the advantages of hepatic cells for toxicology evaluations and screening studies, securing exclusive distribution agreement with upcyte.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.
Servier is set to support two research projects led by UCL to better understand the immune system’s collapse following infections from immune-inflammatory diseases.
Adaptate gains access to Iontas’ platform to select antibodies with optimal biophysical properties for the development of gamma delta T-cell modulating therapeutics.
After one year of collaborative work, Metrion and LifeArc agree to continue research on a joint project focused on neuroscience ion channel drug discovery for another year.
The modeling and simulation solutions provider Simulations Plus has been contracted to support countermeasure development for acute radiation syndrome in a partnership with a global pharma company.
This month’s people on the move includes a new therapeutic lead at Advanced Clinical, with plans to create a network of investigation sites, as well as CEOs at AIT Bioscience and Pharm-Olam, who discuss plans for moving forward.
Escient Pharmaceuticals has entered the market after closing a $40m Series A financing round – and has contacted Eurofins Discovery for integrated drug discovery services.
The online marketplace for outsourced research has expanded its compliance solution to include animal welfare – and is working with customers to increase transparency and educate researchers.
Pepticom’s technology aims to ‘vastly reduce’ risk of failure in peptide drug candidates’ discovery and development, by utilizing artificial intelligence models.
GE Healthcare opens lab space to provide developers with access to protein and cell analysis technologies to encourage networking and partnering on R&D services.
The research models and services provider has acquired a company that specializes in tissue collections, and hematology, and immunology cell isolations to help meet its ‘ever-increasing’ client needs.
Organ-on-a-chip systems are poised to revolutionize drug development in many ways, say researchers advancing the technology, which could support gender-specific medicine, among other use cases.
Charles River Laboratories recently announced that Alzheimer’s Research UK selected the company to join the Dementia Consortium to help researchers progress projects to in vivo proof of concept.
N4 Pharma creates DNA and RNA transfection technology using silica nanoparticles with an irregular surface, which traps and protects nucleic acid during its journey to cells.
GSK taps Lyell’s technology to delay ‘exhaustion’ of T cells and will explore creating a new platform to develop cell and gene therapies for rare cancers.
Insilico Medicine will use its next-generation AI platform to accelerate CRFH’s drug discovery and development efforts – a deal that exemplifies maturation in the market as researchers explore new ways to conduct R&D.
A partnership between Sciex and Protein Metrics aims to make their services compatible with other software services available, enabling drug developers to work in an ‘open ecosystem.’
CAS collates the world’s largest collection of formulations – a ‘one-stop-shop’ that will help formulators innovate faster and solve problems, ultimately reducing drug development timelines, says project lead.
SEngine Precision Medicine raises $5.1m in a Series A investment round to further develop its 3D tumor organoid diagnostic and drug discovery platform.
In Vivo Research Services has developed a 3D visualization technology that provides direct imaging data in real-time, aiming to reduce drug development time and costs.
SEngine Precision Medicine and Atomwise recently announced a new joint venture through which the companies aim to ‘speed and streamline’ new drug discovery, says CEO.
A-Alpha Bio raises $2.8m from venture capital firms and angel investors to further develop its technology – and initiate drug discovery and optimization partnerships with pharmaceutical companies.
PPD is expanding its immunochemistry and biomarker space by 8,000 square feet, the addition of which will also support a dedicated team for one of the company’s global biopharmaceutical clients.
Insilico Medicine brings in $37m to further develop its artificial intelligence work after publishing a study that demonstrates the ‘real-world potential’ of AI for drug discovery – moving the idea from theory to reality.
There has been a lot of discussion surrounding the use of artificial intelligence in drug development – with several deals, alliances, and partnerships made so far this year. Here, Outsourcing-Pharma takes a look back at some of these announcements, as...
The drug discovery and preclinical services company has moved its US office to Kendall Square as it looks to ‘sustainably grow’ its US presence and increase sales in the coming years, says SVP.
Increasingly complex clinical trials are putting pressure on CROs to expand their service offerings in what has been a historically monolithic space – with diagnostics also continuing to play a more important role in the market, says industry expert.
